Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

RTTNews | 539 дней спустя
Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

(RTTNews) - German science and technology major Merck KgaA reported Thursday weak profit and sales in fiscal 2023 amid a challenging market environment. Higher sales in Healthcare business sector were more than offset by weakness in Life Science and Electronics.

Looking ahead for fiscal 2024, Merck expects return to organic growth with slight to moderate organic growth in sales and EBITDA pre, with Healthcare as the main driver.

Further, the Executive Board and Supervisory Board will propose to the Annual General Meeting on April 26 a dividend of 2.20 euros per share, same as last year.

Belen Garijo, Chair of the Executive Board and CEO of Merck, said, "Now, we are fully focusing on gradually returning to growth during fiscal 2024, while defining our strategic roadmap to ensure long term profitable and sustainable growth for Merck."

In fiscal 2023, profit after tax fell 15.1 percent to 2.83 billion euros from last year's 3.34 billion euros. Earnings per share were 6.49 euros, down 15.2 percent from last year's 7.65 euros.

On an adjusted basis, earnings per share pre were 8.49 euros, compared to last year's 10.05 euros.

Operating result or EBIT fell 19.3 percent to 3.61 billion euros from last year's 4.47 billion euros last year. EBIT margin was 17.2 percent, down from 20.1 percent last year.

EBITDA pre fell 14.2 percent year-over-year to 5.88 billion euros, EBITDA margin pre dropped to 28 percent from 30.8 percent last year.

Net sales for the year declined 5.6 percent to 20.99 billion euros from 22.23 billion euros a year ago. Group net sales decreased 1.6 percent organically.

According to the company, the weak results reflected difficult market conditions, including the significant decline in Covid-19-related demand as expected, persistent inventory destocking by key customers of Merck in Process Solutions, as well as the cyclical slowdown in demand for semiconductor materials.

Sales of the Life Science business sector decreased 10.6 percent from last year to 9.28 billion euros. In the Electronics business sector, sales decreased 8.8 percent. In the Semiconductor Solutions business unit, sales decreased organically by 3.9 percent.

Net sales of the Healthcare business sector increased 2.7 percent to 8.05 billion euros, and the growth was 8.5 percent organically.

In Germany, Merck KGaA shares were trading at 158.95 euros, up 0.41 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

read more
Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

German science and technology major Merck KgaA Thursday reconfirmed its earnings and sales forecast for fiscal 2023, but at the lower half of the range after reporting weak profit and sales in its third quarter amid a difficult market environment. Further, the company projects a return to organic sales growth in fiscal 2024. The shares were gaining around 5 percent in the morning trading in German
RTTNews | 658 дней спустя
Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

German science and technology major Merck KgaA reported Thursday higher profit and revenues in its fiscal 2022, with improved performance in all divisions. The company further lifted its dividend, and said it expects weak to flat EBITDA pre in fiscal 2023, but higher organic sales.
RTTNews | 910 дней спустя
Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

While providing updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity on Monday, German science and technology firm Merck KGaA (MKGAY.PK) said it will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation.
RTTNews | 1011 дней спустя
Japan Stock Market May Extend Winning Streak

Japan Stock Market May Extend Winning Streak

The Japan stock market has moved higher in back-to-back sessions, collecting more than 430 points or 1 percent along the way. The Nikkei 225 now rests just beneath the 42,830-point plateau and it may add to its winnings on Friday.
RTTNews | 5 минут назад
KOSPI May Break Through 3,200-Point Level

KOSPI May Break Through 3,200-Point Level

The South Korea stock market has climbed higher in two straight sessions, advancing almost 20 points or 0.6 percent in that span. The KOSPI now sits just shy of the 3,200-point plateau and it may open to the upside again on Friday.
RTTNews | 20 минут назад
Japan Data On Tap For Friday

Japan Data On Tap For Friday

Japan is scheduled to release a batch of data on Friday, headlining a busy day for Asia-Pacific economic activity. On tap are July figures for unemployment, industrial production, retail sales, housing starts and construction orders, as well as August data for household confidence and Tokyo inflation.
RTTNews | 1ч 20мин назад
Euro Climbs Against Majors

Euro Climbs Against Majors

The euro firmed against its major counterparts in the New York session on Thursday.
RTTNews | 1ч 52мин назад